Pim M.
- Country
- The Netherlands
- Department
- Hematology
Research Overview
- Pembrolizumab Plus Bevacizumab Combination Therapy in Patients With Metastatic Cervical Cancer: Registry Study of 12‑Month Progression‑Free Survival
- Phase 3 Randomized Open‑Label Study of KITE‑753 Versus Axicabtagene Ciloleucel in Relapsed or Refractory Large B‑Cell Lymphoma After First‑Line Therapy
- Evaluation of Durvalumab as Adjuvant Therapy in Mismatch Repair-Deficient High-Risk Endometrial Cancer Post-Surgery: A Phase III Clinical Trial
Data & Insights
Has run more than one trial at 17 of 92 partner sites.
Specializations
Ovarian Cancer Research
Specializes in investigating novel therapeutic approaches for recurrent ovarian cancer, with particular focus on platinum-resistant cases and rare subtypes including low-grade serous ovarian cancer and granulosa cell tumors.
- Combination Immunotherapy Studies
- PARP Inhibitor Maintenance Therapy
- Advanced Stage Treatment Strategies
Active in evaluating targeted therapies and immunological approaches for both primary and recurrent disease states.
Endometrial Cancer Studies
Leads research in advanced endometrial carcinoma treatment, with expertise in studying molecular-based therapeutic approaches and maintenance therapy strategies.
- Molecular Profiling Applications
- Immunotherapy Integration
- Post-surgical Treatment Options
Focuses on developing personalized treatment approaches based on specific molecular features of endometrial cancer.
Cervical Cancer Innovation
Investigates cutting-edge treatments for recurrent and metastatic cervical cancer, particularly in second-line and third-line treatment settings.
- Novel Therapeutic Antibodies
- Advanced Stage Disease Management
- Treatment Resistance Solutions
Explores innovative therapeutic approaches for patients who have progressed after standard treatments.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.